Biochemical characterization of transformation-specific proteins of acute avian leukemia and sarcoma viruses

Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein

Myc is a transcription factor driving growth and proliferation of cells and involved in the majority of human tumors. Despite a huge body of literature on this critical oncogene, our understanding of the exact molecular determinants and mechanisms that underlie its function is still surprisingly limited. Indubitably though, its crucial and non-redundant role in cancer biology makes it an attractive target. However, achieving successful clinical Myc inhibition has proven challenging so far, as this nuclear protein is an intrinsically disordered polypeptide devoid of any classical ligand binding pockets. Indeed, Myc only adopts a (partially) folded structure in some contexts and upon interacting with some protein partners, for instance when dimerizing with MAX to bind DNA. Here, we review the cumulative knowledge on Myc structure and biophysics and discuss the implications for its biological function and the development of improved Myc inhibitors. We focus this biophysical walkthrough mainly on the basic region helix-loop-helix leucine zipper motif (bHLHLZ), as it has been the principal target for inhibitory approaches so far.

Cellular MYCro economics: Balancing MYC function with MYC expression

The expression levels of the MYC oncoprotein have long been recognized to be associated with the outputs of major cellular processes including proliferation, cell growth, apoptosis, differentiation, and metabolism. Therefore, to understand how MYC operates, it is important to define quantitatively the relationship between MYC input and expression output for its targets as well as the higher-order relationships between the expression levels of subnetwork components and the flow of information and materials through those networks. Two different views of MYC are considered, first as a molecular microeconomic manager orchestrating specific positive and negative responses at individual promoters in collaboration with other transcription and chromatin components, and second, as a macroeconomic czar imposing an overarching rule onto all active genes. In either case, c-myc promoter output requires multiple inputs and exploits diverse mechanisms to tune expression to the appropriate levels relative to the thresholds of expression that separate health and disease.

The avian erythroblastosis virus erbA oncogene encodes a DNA-binding protein exhibiting distinct nuclear and cytoplasmic subcellular localizations

The protein product of the v-erbA oncogene of avian erythroblastosis virus was analyzed by use of site-specific antisera. The v-erbA protein was found to exist in distinct nuclear and cytoplasmic forms. Both nuclear and cytoplasmic species of the v-erbA protein were capable of binding to DNA, a property predicted based on the structural relatedness the v-erbA polypeptide shares with the thyroid and steroid hormone receptors. A mutation within the v-erbA coding region which inhibited DNA binding and nuclear localization also inhibited the ability of the v-erbA protein to potentiate erythroid transformation, consistent with a model of the v-erbA protein as a transcriptional regulator.

MC29 virus-coded protein occurs as monomers and dimers in transformed cells

The MC29 virus-coded protein p110gag-myc was found exclusively in the nucleus of transformed Japanese quail (Q8) cells, and time course experiments indicated that the protein had a half-life of about 30 min. When extracts of either Q8 or chicken embryo cells infected with MC29 virus were prepared with nondenaturing detergents and then sedimented in sucrose gradients, p110 was found in the fractions expected to contain monomers (5.9S), dimers (9.3S), or mixtures of the two. The same extracts treated with denaturing detergent (0.2% sodium dodecyl sulfate) exhibited p110 only in fractions expected for the monomeric protein, but beta-mercaptoethanol had no effect on the original distribution. Gradients prepared with 0.5 or 1.0 M NaCl failed to dissociate the faster-sedimenting form. No other protein or polyribonucleotide which could increase the sedimentation rate of p110 was found, and neither RNase nor DNase altered the sedimentation pattern of p110 in nondenatured extracts. A reassociation of monomeric p110 into dimers discernible by gel electrophoresis was demonstrated.

Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins

Retroviruses carry cell-derived oncogenes (v-onc) that have the potential to transform cells in culture and induce tumours in vivo. One of the few carcinoma-inducing viruses is the acutely transforming retrovirus MH2, which carries the putative oncogene v-mil and the known oncogene v-myc. Recently, a high degree of homology was discovered between v-mil and v-raf, the transforming gene of the murine retrovirus 3611 murine sarcoma virus (MSV), whereas homology to v-src is low. Both viruses express their oncogenes as the gag-fusion polyproteins p100gag-mil and p75gag-raf (of respective relative molecular mass (Mr) 100,000 and 75,000), while the myc oncogene of MH2 is expressed by means of a subgenomic messenger RNA. We have recently demonstrated that p100gag-mil is not a nuclear protein. Here we report that purified p100gag-mil and p75gag-raf exhibit protein kinase activities in vitro which, in contrast to the src-related p130gag-fps of Fujinami sarcoma virus (FSV) and all other characterized oncogene-encoded protein kinases, phosphorylate serine and threonine but not tyrosine. Both types of protein kinases phosphorylate lipids in vitro.

Decreased DNA-binding ability of purified transformation-specific proteins from deletion mutants of the acute avian leukemia virus MC29

Avian myelocytomatosis virus MC29 is a highly oncogenic replication-defective retrovirus that predominantly affects hematopoietic cells and causes acute leukemia in vivo and that transforms hematopoietic cells as well as fibroblasts in vitro. The transformation-specific sequence, v-myc, is expressed as part of a fusion protein that contains the viral structural protein p19. By use of monoclonal antibodies against p19 we showed that the v-myc-encoded protein is located in the nucleus of MC29-transformed fibroblasts and that after purification over an immunoaffinity column the protein binds to double-stranded DNA. In this report we describe the analysis of the v-myc gene product from MC29-transformed bone marrow cells. The immunoaffinity column-purified protein from these cells also bound to DNA and was indistinguishable from the purified protein from MC29-transformed fibroblasts. In addition, the v-myc gene products from fibroblasts transformed by three nonconditional mutants of MC29--which transform hematopoietic cells with a markedly decreased efficiency in vivo and in vitro but still transform fibroblasts in vitro, expressing deleted v-myc proteins--were analyzed. In contrast to the wild-type protein, the purified mutant proteins had decreased DNA-binding abilities. Furthermore, a preferential binding of the wild-type protein to poly(dG) . poly(dC) duplexes was observed. Such a specificity was lost with a mutant protein. These results provide evidence that the interaction of the v-myc protein with DNA may be directly involved in transformation of the hematopoietic target cells. Further, the transformation-specific fusion proteins purified from cells transformed by avian erythroblastosis virus, which belongs to a different class of acute leukemia viruses, and by Fujinami sarcoma virus were found not to be DNA-binding proteins, suggesting the existence of different transformation mechanisms.